Enveric Biosciences, Inc. · NASDAQ:ENVB
Enveric Biosciences — Investor Presentation (October 2021)
26 slides from Enveric Biosciences's investor presentation, October 2021
Slide 1: Investor Deck October 2021
Investor Deck October 2021 NASDAQ: ENVB
Slide 2: Disclaimer
Disclaimer No Offer or Solicitation This communication is for informational purposes only and is not intended to and does not constitute an offer to sell, or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectu
Slide 3: A platform of next generation psychedelic and cannabinoid medicines
A platform of next generation psychedelic and cannabinoid medicines We leverage our discovery engine and intellectual property portfolio to create next-generation psychedelics and cannabinoids for the mind and body, with lead products in Cancer. 3
Slide 4: Executing with Experience and Passion: Pharma & Biotech Leadership
Executing with Experience and Passion: Pharma & Biotech Leadership Management Team Board of Directors Dr. Joseph Tucker Mr. Avani Kanubaddi David Johnson Dr. Joseph Tucker Chief Executive Officer & President & Chief Operating Officer Executive Chairman Chief Executive Officer & Director Director For
Slide 5: World Class Advisors – Research and Clinical
World Class Advisors – Research and Clinical Arash Asher, M.D. Michael J. Zelefsky, M.D. Scientific Advisor Chairman Dr. Arash Asher is the Director of Cancer Rehabilitation and Survivorship at the Dr. Michael Zelefsky is a board-certified radiation oncologist and co-leader of Memorial Cedars-Sinai
Slide 6: Enveric Bio: A Compelling Investment Thesis
Enveric Bio: A Compelling Investment Thesis • Powerful IP portfolio - 14 Patents filed • Multi-billion-dollar opportunities with large patient populations in mind and body • Psybrary contains 1M+ molecules encompassing Gen2 and Gen3, including non- hallucinogenics • PsyAI allows us to target indicat
Slide 7: Execute on Clinical Assets and Invest in Discovery Assets
Execute on Clinical Assets and Invest in Discovery Assets Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Major Next Steps Timing EV101* GBM Phase 1 Q1 2022 EV102 RD IND Submission Q2 2022 EVM201 CRD Lead Selection Q4 2021 EVM202 PTSD Lead Selection Q1 2022 * Evaluating strategic alternativ
Slide 8: The Platform – Next Generation Medicines
The Platform – Next Generation Medicines Psychedelics MIND Hallucinogenic · Non-Hallucinogenic $70+ Cancer Related Distress $20+B1 BILLION BODY Depression $12+ B2 PTSD Anxiety $990+ M3 $7+ B4 Market $140+ Substance Abuse $31+ B5 Opportunity BILLION Cannabinoids Psychedelics Non-Hallucinogenic Radiod
Slide 9: Initial Focus: Cancer Related Distress (CRD) and Radiodermatitis (RD)
Initial Focus: Cancer Related Distress (CRD) and Radiodermatitis (RD) Billion-dollar opportunities to enhance quality of life for millions of Cancer patients worldwide Radiodermatitis Cancer Related Distress 50% of cancer patients go through Radiation 71% of cancer patients report mental health trea
Slide 10: Psychedelics – Addressing the Mind
Psychedelics – Addressing the Mind 10
Slide 11: Psychedelics: Market and Investor Validation
Psychedelics: Market and Investor Validation Market Validation • J&J Spravato first • FDA Breakthrough • Bio-pharma and Life Science approved Psychedelic Status for 2 Drugs Institutional Investors are putting money to work in a • $3B Estimated Peak • MDMA meaningful way in Revenue Psychedelics • Psi
Slide 12: Psychedelics – Treatments for today and tomorrow
Psychedelics – Treatments for today and tomorrow Optimized NCE for Improved Outcomes Chemically Modified into Prodrugs Classic Psychedelics SSRIs/Current options 12
Slide 13: Psybrary allows us to potentially expand market exponentially
Psybrary allows us to potentially expand market exponentially Current Therapist-delivery model limits the Patient Population Served Gen 1 & 2 Psychedelic Model Psychotherapy with Psychedelics Gen 3 - NCE Model 13
Slide 14: Discovery Team + World-class Laboratories
Discovery Team + World-class Laboratories 14
Slide 15: Psybrary – Engine for Next Generation Molecules
Psybrary – Engine for Next Generation Molecules 15
Slide 16: Psybrary offers Massive Diversity Enabling Generation 2 & 3 Drugs
Psybrary offers Massive Diversity Enabling Generation 2 & 3 Drugs Broad Intellectual Property Coverage Derivative Molecules Classic Molecule Patent Filings Protected Psilocybin & 10 Filed Patents 1 Million+ DMT Mescaline/ 1 Million+ 4 Filed Patents MDMA Possible (1) (1) These figures represent the C
Slide 17: PsyAI – Organizing and Analyzing the vast Psybrary
PsyAI – Organizing and Analyzing the vast Psybrary TM 17
Slide 18: Psychedelic Development Pipeline
Psychedelic Development Pipeline EVM201 (CRD Gen2): EVM301 (CRD Gen3): • Current: Lead Candidate Selection • Current: Target Identification • Next Step: Preclinical Animal Efficacy • Next Step: Assay Development Models EVM202 (PTSD Gen2): EVM302 (PTSD Gen3): • Current: Hit to Lead • Current: Target
Slide 19: Industry Landscape: Rapidly Evolving Sector
Industry Landscape: Rapidly Evolving Sector Company Type Indication Drug Gen 1/2/3 Market Cap DemeRx NASDAQ: ATAI Opioid Use Disorder DMX-NB1 Noribogaine Gen 1 $2.6B Psiliocybin Compass NASDAQ: CMPS Treatment Resistant Depression Gen 1 $1.4B COMP360 MindMed NASDAQ: MNMD Multiple LSD, MDMA, Mescaline
Slide 20: Cannabinoids – Addressing the Body
Cannabinoids – Addressing the Body 20
Slide 21: Human Endocannabinoid System Discovered in the 90s
Human Endocannabinoid System Discovered in the 90s Cannabinoids Tap Into Natural Mechanisms Of Human Body “In the 1990’s, scientists discovered endocannabinoids, the natural cannabis-like molecules produced by the human body. Scientists CB1 CB2 CB1 Receptors Target CB2 Receptors Target began to real
Slide 22: Cannabis & Inflammation
Cannabis & Inflammation Several leading academic institutions from around the globe have been researching the potential for cannabis to treat inflammation, with compelling results. 22
Slide 23: Radiation Dermatitis (RD): $1B Opportunity to Improve High Unmet Need
Radiation Dermatitis(RD): $1B Opportunity to Improve High Unmet Need Current Problem Scientific Hypothesis Enveric Solution Path • 50% cancer patients → radiation • Scientific Evidence: cannabinoids • Enveric novel formulation for RD impacting inflammation • IND Filing Q2 2022 • Radiation Dermatitis
Slide 24: First Nationally Listed Psychedelic and Cannabinoid Biotech Company
:ENVB First Nationally Listed Psychedelic and Cannabinoid Biotech Company Cash and Cash equivalents as of June 30th, 2021 • Cash On-hand - $20.6MM • Debt - Zero Capital Raise • Jan 2021: $9.5 million • Feb 2021: $12.1 million • Warrant exercise (Mar 2021): $3.3 million Issued Shares • Outstanding sh
Slide 25: Expected Catalysts and Milestones
Expected Catalysts and Milestones 2021 2022 EVM202: PTSD EVM201: CRD EV102: RD EVM201: CRD EV102: RD EV101: GBM EVM301: CRD • Lead • Lead Candidate • Murine Model • Animal Model • File IND • Start Phase I/II • Lead Candidate Candidate Selection Study Results Study Results • Start Phase I/II Studies
Slide 26: Building a Discovery & Clinical Platform to Serve the Mind and Body
BUILDING A DISCOVERY & CLINICAL PLATFORM TO SERVE THE MIND AND BODY INVESTOR PRESENTATION (NASDAQ: ENVB) For more information please contact: ir@enveric.com 26
Enveric Biosciences — Investor Presentation (October 2021) on 6ix